Patents by Inventor Malcolm Casale

Malcolm Casale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19
    Publication number: 20240293384
    Abstract: A drug scaffold, MIND-4 and MIND4-17, and derivatives thereof, can be used to treat and prevent infection by SARS-CoV-2 that causes COVID-19, other coronavirus infections, and the associated immune and inflammatory responses. Surprisingly, these compounds inhibit the tubulin network of virally-infected cells, and inhibit viral replication. The compounds and methods described herein are useful in the inhibition of viral replication in a virally-infected cell. The cell can be a cell infected with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), or infected with another SARS coronavirus, or SARS-like coronavirus.
    Type: Application
    Filed: June 29, 2022
    Publication date: September 5, 2024
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Malcolm Casale, Leslie M. Thompson, Thomas E. Lane
  • Small molecule activators of NRF2 pathway
    Patent number: 9737525
    Abstract: This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: August 22, 2017
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Aleksey G. Kazantsev, Leslie M. Thompson, Ruben Abagyan, Malcolm Casale
  • SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY
    Publication number: 20160101098
    Abstract: This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
    Type: Application
    Filed: June 6, 2014
    Publication date: April 14, 2016
    Applicant: The Regents of the University of California
    Inventors: Aleksey G. Kazantsev, Leslie M. Thompson, Ruben Abagyan, Malcolm Casale